Blonanserin (development code AD-5423; brand name Lonasen®) is a second-generation atypical antipsychotic developed by Dainippon Sumitomo Pharma. It is approved in Japan and China for the treatment of schizophrenia. Unlike many atypical antipsychotics that act on multiple receptor targets, blonanserin has a relatively selective receptor profile, primarily antagonizing dopamine D₂/D₃ and serotonin 5-HT₂A receptors.

differentiator: Blonanserin has high selectivity for D₂/D₃ receptors over D₁ receptors and low affinity for histamine H₁, muscarinic M₁, and α₁-adrenergic receptors. This translates to a favorable side effect profile with lower risks of weight gain, sedation, and metabolic syndrome compared to other atypical antipsychotics (e.g., olanzapine, quetiapine, risperidone).

Synonyms:

• AD-5423

• Lonasen

• Bunanserin

• 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine

Supplier: LyvBio Co., Ltd.

LyvBio 주식회사. is a supplier of high-purity Blonanserin for pharmaceutical research and development.

Supply capabilities:

• Purity: ≥99.0% (HPLC)

• Monthly capacity: 20+ kg

• Bulk quantities: 10g – 50kg

• Lead time: 3–5 days (samples), 10–15 days (bulk)

• Documentation: COA,  HPLC chromatogram, stability data

📧 Inquiries: info@lyvbio.com

Specifications